Claudin 1 Promotes Migration and Increases Sensitivity to Tamoxifen and Anticancer Drugs in Luminal-like Human Breast Cancer Cells MCF7

REFERENCES

• Canadian Cancer Society. Canadian cancer statistics. Available at http://www.cancer.ca. 2014.
   Google Scholar
• Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346–352.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000;406:747–752.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869–10874.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2008;26:1275–1281.
   PubMed Web of Science ®Google Scholar
• Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, Yakirevich E. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol 2013;26:485–495.
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin.Cancer Res 2005;11:5678–5685.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang N, Fang J, Huang J, Tian F, Li C, Xie F. Role of PKC–ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncol Rep 2012;27:1879–1886.
   PubMed Web of Science ®Google Scholar
• Lagadec C, Adriaenssens E, Toillon RA, Chopin V, Romon R, Van Coppenolle F, Hondermarck H, Le Bourhis X. Tamoxifen and trail synergistically induce apoptosis in breast cancer cells. Oncogene 2008;27:1472–1477.
   PubMed Web of Science ®Google Scholar
• Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, Tian R, Foley KM, Bowman T, Miron A, Brown M, Iglehart JD, Biswas DK. Nf-kappab activation-induced anti-apoptosis renders her2-positive cells drug resistant and accelerates tumor growth. Mol Cancer Res: MCR 2014;12:408–420.
   PubMed Web of Science ®Google Scholar
• Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat.Rev.Clin.Oncol 2010;7:683–692.
   PubMed Web of Science ®Google Scholar
• Berx G, van RF. The e-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001;3:289–293.
   PubMed Web of Science ®Google Scholar
• Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 2007;39:2153–2160.
   PubMed Web of Science ®Google Scholar
• Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305–318.
   PubMed Web of Science ®Google Scholar
• Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003;83:337–376.
   PubMed Web of Science ®Google Scholar
• Gonzales-Mariscal L. Tight junctions. Boca Raton: CRC Press; 2001.
   Google Scholar
• Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005;65:9603–9606.
   PubMed Web of Science ®Google Scholar
• Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285–293.
   PubMed Web of Science ®Google Scholar
• Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A, Tsukita S. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002;156:1099–1111.
   PubMed Web of Science ®Google Scholar
• Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 1999;9:268–273.
   PubMed Web of Science ®Google Scholar
• Tsukita S, Furuse M. Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol 2002;14:531–536.
   PubMed Web of Science ®Google Scholar
• Yoon C-H, Kim M-J, Park M-J, Park I-C, Hwang S-G, An S, Choi Y-H, Yoon G, Lee S-J. Claudin-1 acts through c-abl-protein kinase cdelta (pkcdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem 2010;285:226–233.
   PubMed Web of Science ®Google Scholar
• Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005;115:1765–1776.
   PubMed Web of Science ®Google Scholar
• Takehara M, Nishimura T, Mima S, Hoshino T, Mizushima T. Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biol Pharm Bull 2009;32:825–831.
   PubMed Web of Science ®Google Scholar
• Leotlela PD, Wade MS, Duray PH, Rhode MJ, Brown HF, Rosenthal DT, Dissanayake SK, Earley R, Indig FE, Nickoloff BJ, Taub DD, Kallioniemi OP, Meltzer P, Morin PJ, Weeraratna AT. Claudin-1 overexpression in melanoma is regulated by pkc and contributes to melanoma cell motility. Oncogene 2007;26:3846–3856.
   PubMed Web of Science ®Google Scholar
• Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type mmp-1. Cancer Res 2006;66:5251–5257.
   PubMed Web of Science ®Google Scholar
• Tokés A-M, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z. Claudin-1, -3 and -4 proteins and MRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res: BCR 2005;7:R296–305.
   PubMed Web of Science ®Google Scholar
• Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, Young TL, Leygue E, Myal Y. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arc: Int J Pathol 2009;454:647–656.
   PubMed Web of Science ®Google Scholar
• Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, Hakamada K, Sasaki M, Kijima H. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 2007;20:139–143.
   PubMed Web of Science ®Google Scholar
• Dong C, Chen L. Second malignancies after breast cancer: the impact of adjuvant therapy. Mol Clin Oncol 2014;2:331–336.
   Google Scholar
• Campbell MT, Dagher P, Hile KL, Zhang H, Meldrum DR, Rink RC, Meldrum KK. Tumor necrosis factor-alpha induces intrinsic apoptotic signaling during renal obstruction through truncated bid activation. J Urol 2008;180:2694–2700.
   PubMed Web of Science ®Google Scholar
• Yin XM. Signal transduction mediated by bid, a pro-death bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res 2000;10:161–167.
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y. Proliferation, hormonal responsiveness, and estrogen receptor content of mcf-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987;47:4355–4360.
   PubMed Web of Science ®Google Scholar
• Yan Y, Penner CC, Skliris GP, Cooper C, Nugent Z, Blanchard A, Hamedani MK, Wang X, Myal Y, Murphy LC, Leygue E. Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors. J Cancer Res Clin Oncol 2013;139:1637–1647.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Carvajal RD, Merrill AH, Jr., Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of Safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res 2011;17:2484–2492.
   PubMed Web of Science ®Google Scholar
• Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514–1521.
   PubMed Web of Science ®Google Scholar
• Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003;63:8977–8983.
   PubMed Web of Science ®Google Scholar
• Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M, Kaina B. Long-term activation of SAPK/JNK, p38 kinase and fas-l expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. International journal of cancer. J Int Cancer 2004;112:974–985.
   PubMed Web of Science ®Google Scholar
• Chandra D, Choy G, Deng X, Bhatia B, Daniel P, Tang DG. Association of active caspase 8 with the mitochondrial membrane during apoptosis: potential roles in cleaving bap31 and caspase 3 and mediating mitochondrion-endoplasmic reticulum cross talk in etoposide-induced cell death. Mol Cell Biol 2004;24:6592–6607.
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Yoshikawa H, Shiiki K, Hamada Y, Nakajima Y, Tasaka K. Cisplatin (CDDP) sensitizes human osteosarcoma cell to fas/cd95-mediated apoptosis by down-regulating flip-l expression. International journal of cancer. J Int cancer 2000;88:986–991.
   PubMed Web of Science ®Google Scholar
• Nagarkatti N, Davis BA. Tamoxifen induces apoptosis in fas+ tumor cells by upregulating the expression of fas ligand. Cancer Chemot Pharm 2003;51:284–290.
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, Jr., de SM, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603–607.
   PubMed Web of Science ®Google Scholar
• Dhawan P, Singh AB, Deane NG, No Y, Shiou S-R, Schmidt C, Neff J, Washington MK, Beauchamp RD. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005;115:1765–1776.
   PubMed Web of Science ®Google Scholar
• Di Cello F, Cope L, Li H, Jeschke J, Wang W, Baylin SB, Zahnow CA. Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer. PloS one 2013;8:e68630–e68630.
   PubMed Web of Science ®Google Scholar
• Kovalenko OV, Yang XH, Hemler ME. A novel cysteine cross-linking method reveals a direct association between claudin-1 and tetraspanin cd9. Mol Cell Proteomics 2007;6:1855–1867.
   PubMed Web of Science ®Google Scholar
• Fortier A-M, Asselin E, Cadrin M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation. J Biol Chem 2013;288:11555–11571.
   PubMed Web of Science ®Google Scholar
• Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible tgfbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009;11:1287–1296.
   PubMed Web of Science ®Google Scholar
• Leivonen SK, Kahari VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. International journal of cancer. J Int Cancer 2007;121:2119–2124.
   PubMed Web of Science ®Google Scholar
• Lesko E, Majka M. The biological role of HGF-met axis in tumor growth and development of metastasis. Front Biosci: J Virtual Libr 2008;13:1271–1280.
   PubMed Web of Science ®Google Scholar
• Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31–101.
   PubMed Web of Science ®Google Scholar
• Grande M, Franzen A, Karlsson JO, Ericson LE, Heldin NE, Nilsson M. Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (emt) through a mek-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci 2002;115:4227–4236.
   PubMed Web of Science ®Google Scholar
• Kojima T, Takano K, Yamamoto T, Murata M, Son S, Imamura M, Yamaguchi H, Osanai M, Chiba H, Himi T, Sawada N. Transforming growth factor-beta induces epithelial to mesenchymal transition by down-regulation of claudin-1 expression and the fence function in adult rat hepatocytes. Liver Int 2008;28: 534–545.
   PubMed Web of Science ®Google Scholar
• Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC. TbetaRIII/beta-arrestin2 regulates integrin alpha5beta1 trafficking, function, and localization in epithelial cells. Oncogene 2013;32:1416–1427.
   PubMed Web of Science ®Google Scholar
• Tang L, Feng J. SPARC in tumor pathophysiology and as a potential therapeutic target. Curr Pharm Des 2014.
   Google Scholar
• Long BH, Musial ST, Brattain MG. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 1985;45:3106–3112.
   PubMed Web of Science ®Google Scholar
• Akasaka H, Sato F, Morohashi S, Wu Y, Liu Y, Kondo J, Odagiri H, Hakamada K, Kijima H. Anti-apoptotic effect of claudin-1 in tamoxifen-treated human breast cancer mcf-7 cells. BMC Cancer 2010;10:548.
   PubMed Web of Science ®Google Scholar
• Li S, Zhou Y, Dong Y, Ip C. Doxorubicin and selenium cooperatively induce fas signaling in the absence of fas/fas ligand interaction. Anticancer Res 2007;27:3075–3082.
   PubMed Web of Science ®Google Scholar
• Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PR. Apoptotic mechanisms in t47d and mcf-7 human breast cancer cells. Br J Cancer 2002;87:909–917.
   PubMed Web of Science ®Google Scholar
• Heerma van Voss MR, van Diest PJ, Smolders YH, Bart J, van der Wall E, van der Groep P. Distinct claudin expression characterizes brca1-related breast cancer. Histopathology 2014;65:814–827.
   PubMed Web of Science ®Google Scholar
• Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y. Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 2013;13: 268.
   PubMed Web of Science ®Google Scholar
• Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, Yakirevich E. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol:Off J US Can Acad Pathol, Inc 2013;26:485–495.
   PubMed Web of Science ®Google Scholar
• Myal Y, Leygue E, Blanchard AA. Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers. J Biomed Biotechnol 2010;2010:956897.
   PubMed Web of Science ®Google Scholar